Press Alleges Judge is Dodging Coverage in Texas Abortion Pill Case
A federal court in Northern Texas could revoke the FDA approval of an abortion medication, which would alter abortion policy across the country.

A ruling could come at any moment in a Texas case that could take a widely used abortion medication off the market nationwide, even in states where abortion remains legal.
The Texas lawsuit concerns the FDA approval of mifepristone, which has been used in America since 2000 and has been used in other countries, such as France, since the 1980s.
Judge Matthew Kacsmaryk of the Northern District of Texas, who is known for his anti-abortion beliefs, could rule on the issue at any point.
Judge Kacsmaryk has also faced criticism from the News Media Coalition for alleged efforts to prevent coverage and protest at Wednesdayâs hearing.

The group said in a court filing that the judge intentionally delayed entering Wednesdayâs hearing into the public schedule to âlimit the ability of members of the public, including the pressâ to attend the hearing.
In a filing Monday, the organization called on the court to âimmediately docket the hearing scheduled for Wednesdayâ and to ârescind any request made to parties and their counsel not to discuss the hearing schedule in this case publicly.â
âAcross the ideological spectrum, the public is intensely interested in this case,â attorney Peter Steffensen wrote on the organizationâs behalf. âThe Court cannot constitutionally close the courtroom indirectly when it cannot constitutionally close the courtroom directly.â
Following Mondayâs complaint, Judge Kacsmaryk ordered the court to officially schedule Wednesdayâs meeting, which took place at Amarillo, Texas.
This case has drawn significant attention because Judge Kacsmaryk has been historically vocal about his personal opposition to abortion and his ruling will not even have an affect on the Northern District of Texas due to Texasâs ban on abortions.
After Roe v. Wade was overturned last summer, the conservative Christian legal advocacy group Alliance Defending Freedom brought the case in November, alleging that the drug, which has been used for decades, was unsafe.
If Judge Kacsmaryk were to rule in favor of revoking the drugâs FDA approval, then the drug would become unavailable nationwide, regardless of state law.
The executive director of the Womenâs March, Rachel Carmona, said that the case was not about the safety of the drug but rather an attempt to limit access to abortion care nationwide.
âThis isnât about what the overwhelming majority of Americans want; itâs about a small group of people who want control over womenâs freedom to choose,â Ms. Carmona said.
The Alliance Defending Freedom contends that the FDA has âcompletely failed its statutory duties to protect women and girls,â according to their senior counsel, Julie Blake.
The issue also spurred action from a group of Democratic-led state governments, which brought a competing case in the Eastern District of Washington.
Nevada, Delaware, Arizona, Illinois, Connecticut, Colorado, Vermont, New Mexico, Michigan, and Rhode Island joined Washington in a complaint alleging that the FDA is restricting mifepristone unduly.
The Washington attorney general, Bob Ferguson, said that the âFDAâs excessive restrictions on this important drug have no basis in medical science.â
The case in Washington, which will likely be resolved after the case in Texas, could create a conflicting ruling to the case in Texas, which would require a resolution from a higher court, like the Supreme Court.